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IMPORTANCE Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
(ALSP) is a frequent cause of adult-onset leukodystrophy known to be caused by autosomal
dominant mutations in the CSF1R (colony-stimulating factor 1) gene. The discovery that CSF1R
mutations cause ALSP led tomore accurate prognosis and genetic counseling for these
patients in addition to increased interest in microglia as a target in neurodegeneration.
However, it has been known since the discovery of the CSF1R gene that there are patients
with typical clinical and radiologic evidence of ALSP who do not carry pathogenic CSF1R
mutations. These patients include those in whom the pathognomonic features of axonal
spheroids and pigmentedmicroglia have been found. Achieving a genetic diagnosis in these
patients is important to our understanding of this disorder.
OBJECTIVE To genetically characterize a group of patients with typical features of ALSP who
do not carry CSF1Rmutations.
DESIGN, SETTINGS, AND PARTICIPANTS In this case series study, 5 patients from 4 families
were identified with clinical, radiologic, or pathologic features of ALSP in whom CSF1R
mutations had been excluded previously by sequencing. Data were collected between
May 2014 and September 2015 and analyzed between September 2015 and February 2016.
MAIN OUTCOMES ANDMEASURES Focused exome sequencingwas used to identify candidate
variants. Family studies, long-range polymerase chain reaction with cloning, and
complementary DNA sequencing were used to confirm pathogenicity.
RESULTS Of these 5 patients, 4 were men (80%); mean age at onset of ALSP was 29 years
(range, 15-44 years). Biallelic mutations in the alanyl-transfer (t)RNA synthetase 2 (AARS2)
gene were found in all 5 patients. Frameshifting and splice site mutations were common,
found in 4 of 5 patients, and sequencing of complementary DNA from affected patients
confirmed that the variants were loss of function. All patients presented in adulthood with
prominent cognitive, neuropsychiatric, and upper motor neuron signs. Magnetic resonance
imaging in all patients demonstrated a symmetric leukoencephalopathy with punctate
regions of restricted diffusion, typical of ALSP. In 1 patient, brain biopsy demonstrated axonal
spheroids and pigmentedmicroglia, which are the pathognomonic signs of ALSP.
CONCLUSIONS AND RELEVANCE This work indicates that mutations in the tRNA synthetase
AARS2 gene cause a recessive form of ALSP. The CSF1R and AARS2 proteins have different
cellular functions but overlap in a final common pathway of neurodegeneration. This work
points to novel targets for research and will lead to improved diagnostic rates in patients with
adult-onset leukoencephalopathy.
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A dult-onset genetic leukoencephalopathies comprise adiverse group of degenerative white matter disorderswith an ever-increasing number of associated genes.1
Most patients present with a variable phenotype of cognitive
decline, neuropsychiatric disturbance, andpyramidal andex-
trapyramidal signs. Theoften-overlapping symptomsand fre-
quently similar magnetic resonance imaging (MRI) patterns
mean that, even with systematic testing, one-third of pa-
tients donot receive a genetic diagnosis.2 In addition, the cost
of comprehensivemetabolic andgenetic screeningmaybepro-
hibitive inmanyhealth care settings.Despite these factors, de-
finitive genetic diagnosis is the only way that patients can be
given appropriate genetic counseling or a relatively accurate
prognosis.
Adult-onset leukoencephalopathywith axonal spheroids
andpigmentedglia (ALSP) is themost frequentadult-onset leu-
kodystrophy and is caused by autosomal dominant muta-
tions in the CSF1R (colony-stimulating factor 1) gene (OMIM:
164770).3 The clinical andpathologic features ofALSParewell
defined4-6;however, severalapparently typical caseshavebeen
shown7 not to possess CSF1Rmutations.
Alanyl-transfer (t)RNA synthetase 2 (AARS2) is a gene
(OMIM:612035) encoding the tRNAsynthetase responsible for
loadingalanine (ala)onto tRNA-aladuringmitochondrial trans-
lation. In 2011, the first association of AARS2 mutations and
humandiseasewas published,8when 3 patientswith fatal in-
fantile cardiomyopathyweredescribedwith autosomal reces-
sive mutations in the gene. Later, Dallabona et al9 described
6patientswithovarioleukodystrophywhowere found tohave
AARS2mutations by whole-exome sequencing. The MRI ap-
pearance was nonspecific and consisted of signal abnormal-
ity in the frontal,parietal, andperiventricularwhitematterwith
involvement of the corpus callosum and patchy areas of re-
stricteddiffusionondiffusion-weighted imaging.Nobrain tis-
sue was available for pathologic examination in any AARS2
cases.
In this study, we describe 5 patients with an adult-onset
phenotype typical of ALSP who were found to carry com-
pound heterozygous or homozygousmutations inAARS2. Of
these patients, 4 weremen (80%); mean age at onset of ALSP
was 29years (range, 15-44years). In addition,wedescribe, for
what we believe to be the first time, the central nervous sys-
tempathologic features ofAARS2-related leukoencephalopa-
thy in which frequent axonal spheroids and pigmented mi-
croglia were seen. We provide an explanation for several
patientswithCSF1R-negativeALSP,particularly thosewithap-
parently sporadic onset, in whom recessive AARS2 muta-
tions should be suspected.
Methods
Patientswere selected if therewas clinical and radiologic evi-
denceofALSP, definedas anadult-onset disorderwithpromi-
nent cognitive, neuropsychiatric, parkinsonian, or uppermo-
tor neuron signs accompanied by symmetric T2-weighted
hyperintensity of the white matter on MRI with patchy areas
of restricteddiffusion.All patientshadpreviouslybeen shown
not to carryCSF1Rmutationsby resultsof conventional Sanger
sequencing. This study was carried out with approval of the
UniversityCollegeLondonHospitalTrust, andall patientsgave
written informed consent to participate. There was no finan-
cial compensation. Data were collected between May 2014
and September 2015 and analyzed between September 2015
and February 2016.
Focused exome sequencing was performed (Agilent Sure
Select FocusedExomekit; Agilent Technologies) according to
themanufacturer’sprotocol.After librarypreparationandcap-
ture, thepooled librariesweresequenced(IlluminaHiSeq1500;
Illumina). FastQ sequencing data were aligned (Novoalign
Software; Novocroft Technologies). Variants were extracted
using the Macmodel in SAMtools10 and calls were annotated
usingAnnovar software.11Mean target coveragewas40×,with
92% of target bases reading more than 10×.
If familial DNAwasnot available to phase compoundhet-
erozygousmutations, we cloned long polymerase chain reac-
tion (PCR) products containing the genomic region spanning
bothvariants intoTOPOvectors (pCR2.1-TOPOTAvector;Ther-
moFisher Scientific), transformed bacteria, and used colony
PCR to determine whether the variants were on the same or
different alleles.Wedetermined the impact of splice site vari-
ants by sequencing complementaryDNA (cDNA)derived from
patient tissue when available. Skin biopsies were performed
and fibroblasts were cultured in a medium (Dulbecco modi-
fied Eagle medium; ThermoFisher Scientific) containing
L-glutamine supplementedwith 10%fetal calf serum.We then
extracted RNA and reverse transcribed it to cDNA before PCR
amplificationandsequencingwithcDNA-specificprimers that
spanned exon-exon junctions.
Results
Clinical Descriptions
Patient 1
This woman had normal childhood and adolescent develop-
ment until her early 20s, when she was diagnosed with der-
matomyositisandrequiredtreatmentwithcorticosteroids,aza-
thioprine sodium,andmycophenolatemofetil. Shedeveloped
Key Points
Question What is the genetic cause of adult-onset
leukoencephalopathy with axonal spheroids and pigmented glia
(ALSP) in patients with typical features who are negative for
mutations in the CSF1R (colony-stimulating factor 1) gene?
Findings In this case series study, using focused exome
sequencing, bilallelic mutations in the AARS2 (alanyl-transfer
[t]RNA synthetase 2) gene were identified in 5 patients with
typical clinical, radiologic, and pathologic features of ALSP.
Frameshifting and splice site mutations were common.
Meaning Screening the AARS2 gene should be considered in all
patients with adult-onset leukodystrophy with clinical or radiologic
features suggesting ALSP.
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premature ovarian failure in her mid-20s. Mild neuropsychi-
atric symptomsdevelopedwhen shewas inher early 40s con-
sisting of problems with mental calculation and generalized
anxiety. These symptoms progressed and she became ataxic,
with an asymmetric spastic paraparesis and left upper limb
apraxia.Within 2 years of onset, there wasmarked apraxia in
the left hand with weakness of finger extension and severe
spasticity of the left leg. There were signs of a cortical sen-
sory syndrome involving the parietal lobe with sensory inat-
tention to the left.Magnetic resonance imaging scanningdem-
onstratedsymmetric confluentareasofhighsignal in thewhite
matter on T2-weighted images. The presence of whitematter
abnormalities in anypatient receiving long-term immunosup-
pression raised a concern for progressivemultifocal leukoen-
cephalopathy, which prompted a right parietal biopsy.
Right parietal biopsy findings demonstrated myelin loss
with rarefaction and gliosis in the white matter and numer-
ous axonal spheroids (Figure 1). The spheroids were accom-
panied by dystrophic axonal profiles and accumulated neu-
rofilaments, p62, amyloid precursor protein, and β-amyloid.
Scattered macrophages and microglia were also present and
were intensely reactive for CD68. The macrophages accumu-
lated light brown cytoplasmic lipopigment that was stained
by periodic acid–Schiff, was diastase resistant, and was
Figure 1. Right Parietal Biopsy Specimens FromPatient 1
Axonal spheroidsA Pigmented cellsB Myelin pallorC
PAS positivityEAbnormal axonal profilesD
CD68 immunostainingF
A and B, Rarified and gliotic white matter containing scattered eosinophilic
axonal swellings (spheroids) and pigmented cells containing light brown
lipopigment (B, inset). C, Myelin pallor and severe loss of myelinated axons.
Immunostaining with an antibody against a cocktail of high- and
low-molecular-weight neurofilaments showed numerous axonal spheroids with
accentuated labeling at the periphery of the swellings. D, In addition, several
dystrophic, swollen, and beaded axonal profiles were seen. E, The pigmented
cells were strongly positive for periodic acid–Schiff (PAS) staining and
colocalized granular CD68 immunoreactivity (F), suggesting lysosomal
localization. (A-D and F: hematoxylin-eosin, original magnification ×50;
E: Luxol fast blue, original magnification ×20).
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intensely autofluorescent in unstained sections. Skeletal
muscle biopsies taken at ages 20 and 40 years showed typi-
cal features of dermatomyositis as well as several fibers with
complete or partial cyclooxygenase depletion (sequential
cyclooxygenase-succinate dehydrogenase histochemistry).
This defect was accentuated in the zones of perifascicular
atrophy.
Patient 2 and Patient 3
Patient 2 was a man in his late 30s from Turkey who pre-
sented with a rapidly evolving neurologic syndromewith se-
vere neuropsychiatric and behavioral changes. He developed
obsessive behavior and hyperphagia with profound execu-
tive dysfunction and memory impairment. The behavioral
changes required treatmentwithhaloperidol. Examination re-
vealed grossly normal tone and power, with a normal gait.
There was an asymmetric, coarse upper limb tremor during
rest,posture, andaction.Thesyndromerapidlyprogressedand
he required residential care within 1 year of onset.
This patient’s brother (patient 3)was similarly affectedby
a rapidly progressive neurodegenerative syndrome with on-
set in his mid-20s. We did not examine him. The family re-
ported a similar disease, characterized by progressive diffi-
culty with speech and swallowing with rapid motor decline.
He became bed bound and died within 1 year of onset of the
disease. Patient 3 did not experience the profound neuropsy-
chiatric disorder found in his brother.
Patient 4
This patient was a young man of South Asian ancestry who
had normal physical and cognitive development until
middle adolescence, when he began to develop subtle psy-
chiatric symptoms and decline in school performance. Dur-
ing the next 2 years, he became disinhibited and developed
an ataxic gait with visual disturbance. Psychotic symptoms
developed and he required treatment with quetiapine fuma-
rate. There was no significant medical history and no signs
of endocrine disease or hypogonadism. There was no family
history of neurologic disease or known consanguinity. The
examination revealed an asymmetric spastic paraparesis
with bradykinesia and dystonic posturing of the hands. Cer-
ebellar ataxia and dysdiadochokinesis were present with
generalized hyperreflexia and bilateral extensor plantar
responses. Moderate progression of symptoms occurred dur-
ing the next 2 years, and the patient died in late adolescence
from complications of the disease.
Figure 2. Typical Magnetic Resonance Imaging Appearance inAARS2-Related Leukodystrophy
T2 hyperintense white matterA FLAIR suppressionB DWI restricted diffusionC
Pyramidal tract involvementE Corpus callosumF DWI restricted diffusionG
Apparent diffusion coefficientD
Apparent diffusion coefficientH
Asymmetric T2 hyperintensity in the deep and periventricular white matter (A)
with fluid-attenuated inversion recovery (FLAIR) suppression (B) are noted in
patient 2, indicating white matter rarefaction. There are punctate areas of
restricted diffusion seen in the diffusion-weighted imaging (DWI) (C) and
apparent diffusion coefficient images at the level of the centrum semiovale (D).
Asymmetric pyramidal tract involvement (E) with thinning of the corpus
callosum and hypointense signal in the genu, body, and splenium (F). In
patient 4, there was evidence of restricted diffusion in the splenium of the
corpus callosum on the DWI (G) and apparent diffusion coefficient (H) images.
Research Original Investigation Analysis of Mutations in AARS2 in a Series of CSF1R-Negative Patients
1436 JAMANeurology December 2016 Volume 73, Number 12 (Reprinted) jamaneurology.com
Downloaded From: http://jamanetwork.com/ by a University College London User  on 07/20/2017
Copyright 2016 American Medical Association. All rights reserved.
Patient 5
Aman in hismid-40s fromTurkey presentedwith a 1-year his-
tory of right upper limbdystonia anddysarthria. This develop-
mentwas followedbycognitivedeteriorationandneuropsychi-
atricsymptomsincludingdepressionandaggressivebehavior.He
developedpsychosisandwastreatedwitholanzapine.Therewas
nofamilyhistoryofneurologicdiseaseandnoknownconsanguin-
ity.Hehadnosignificantmedicalhistory; inparticular, therewas
nohistoryofendocrinediseaseorhypogonadism.Onexamina-
tion, saccadeswereslowedandhehadapseudobulbarpalsy.He
exhibited anasymmetric spastic quadriparesiswithprominent
right-sideddystoniaandparkinsonism.Therewasnoweakness
orsensorychangesonexamination.Thispatient’sconditionrap-
idly deteriorated andhedied 1 year after symptomonset.
MRI Findings
Magnetic resonance imaging findings were consistent among
all patients (Figure2). The typical appearancewasofasymmet-
ric, confluent T2-weighted hyperintensity in the frontopari-
etalwhitematterwith involvement of the immediate periven-
tricularwhitematter in themost severely affected areas. Clear
demonstration of white matter rarefaction in the peritrigonal
regions that suppressed on fluid-attenuated inversion recov-
erysequenceswasseeninallcases.ThesubcorticalUfiberswere
affectedonly intheareasofgreatestsignalabnormality.Thecor-
puscallosumwasslightly thinned,withhighsignal in thegenu,
body,andsplenium.Anotherconsistent imagingfeaturewasthe
asymmetric involvementof thepyramidal tractsextending into
the posterior limb of the internal capsules and the brainstem.
In all patients, there were punctate and partly confluent areas
of restricted diffusion, seen especially in the centrum semi-
ovale, corona radiate, and spleniumof the corpus callosum. In
patient 1, for whom serial imaging was available, the areas of
restricted diffusion persisted on an MRI for at least 7 months.
None of the lesions enhanced after administration of intrave-
nous gadolinium contrast.
Figure 3. Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Analysis of Splice Site Variants
Exon 9
Exon 5 Exon 7
c.1041-1G>A splicing effectA
4 5 6 7
c.595C>T
4 5 6 7
c.1041-1G>A
C C C C C C C CTT T T T T TG G G G GA A A A G
CT
L
P1
Exon 7
c.1188G>A splicing effectB
8 9 10 11
c.1188G>A
8 9 10 11
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A, Schematic representation of the
alanyl-transfer RNA synthetase 2
(AARS2) gene and results of RT-PCR
analysis of complementary DNA
(cDNA) from patient 1 (P1).
Polymerase chain reaction of a cDNA
fragment spanning exons 3 to the
junction of exons 9 and 10 produced
2 differently sized PCR products in P1
compared with the control (CTL). The
lower band, indicated by the white
arrowhead, was gel extracted and
sequenced. Sequence analysis
demonstrated that the lower band
resulted from abnormal splicing with
exclusion of exon 6. B, Results of PCR
analysis of cDNA from patient 2 (P2).
Reverse-transcriptase PCR of a cDNA
fragment spanning exons 6 to the
junction of exons 9 and 10 produced
2 differently sized PCR products in P2
compared with the CTL. The lower
band, indicated by the white
arrowhead, was gel extracted and
sequenced. Sequence analysis
demonstrated that the lower band
resulted from abnormal splicing with
exclusion of exon 8.
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Genetic Findings
We identified biallelic mutations in AARS2 in 5 patients from
4 families using focused exome sequencing. In patient 1, we
detected a novel c.1041-1G>Amutation in the splice acceptor
site of exon 7. Analysis of cDNA from patient tissue con-
firmed that the mutation leads to abnormal splicing with ex-
clusion of exon 6 (Figure 3). In trans was the previously re-
ported c.595C>T, p. R199C variant.
In patients 2 and 3, we detected a novel synonymous
mutation affecting the last nucleotide of exon 8 (c.1188G>A).
Analysis of cDNA from fibroblasts of patient 2 demonstrated
that the mutation leads to abnormal splicing with exclusion
of exon 8 (Figure 3). In transwas another variant (c.1709delG)
that leads to a frameshift with premature termination
(p. G570Afs*21).
Patient 4was found to carry the compoundheterozygous
c.[892_894del]; [2234_2235del]mutations. The c.892_894del
leads to an inframe deletion of the last codon of exon 5 p.
(298_298delQ) and may affect normal splicing of the tran-
script. The c.2234_2235 deletion leads to a frameshift with a
predicted premature termination codon p.(Ser745Cysfs*60).
Tissuewasnot available to assess the variants’ effect onRNA.
Patient 5 was found to be homozygous for the c.595C>T,
p.R199C variant, which was shown12 previously to affect the
aminoacylation activity of the AARS2 protein.
Discussion
Adult-onset leukodystrophies and genetic leukoencephalopa-
thiesoftenpresentadiagnosticchallengewithoverlappingclini-
cal phenotypes andMRI findings that lead to anexpensive and
lengthydiagnosticodyssey.13 The identificationandcharacter-
ization of the ALSP-associated CSF1R gene providedmany pa-
tients and families with a precise genetic diagnosis, although
manyadult-onset leukodystrophies remainundefined.Theuse
of exome sequencinghas advancedour diagnostic capabilities
with the discovery of several new leukodystrophy genes, and
deep clinical and radiologic phenotyping are leading to im-
proveddiagnostic rates.14,15 In this study,we show that typical
ALSP cases can be caused by mutations in CSF1R and AARS2,
withMRI findings that typically demonstrated an asymmetric
confluent T2 hyperintensity in the frontoparietal and periven-
tricular whitematter with rarefaction.
Neuroaxonal swellings, the larger of which are known as
spheroids, are a morphologic abnormality of axons of uncer-
tain pathogenesis with proposed wallerian and nonwallerian
mechanisms9 that can occur in the central and peripheral
nervous systems. Spheroids are associated with a variety of
conditions, including physiologic aging, acute axonal injury,
as being around infarcts or foci of demyelination, and as an
integral feature in certain heritable neurodegenerative con-
ditions predominantly affecting the gray matter as with neu-
rodegeneration with brain iron accumulation16,17 or the
white matter as in leukodystrophy. The combination of
adult-onset leukodystrophy with axonal spheroids and pig-
mented microglia has been believed to be highly suggestive,
if not pathognomonic, of CSF1R-related disease.3,18-20 In this
study, we show that these pathologic changes are not spe-
cific and that mutations in AARS2 can lead to an identical
clinical, radiologic, and tissue phenotype to ALSP. In
women, at least, the presence of premature ovarian failure
may provide a clue that AARS2 is responsible, but no such
clue exists for men (Table).
Conclusions
We advocate for increasing adoption of next-generation se-
quencing approaches in the routine care of patients with
genetic leukoencephalopathies. However, when such ap-
proaches are not available, we recommend screening formu-
tations in CSF1R and AARS2 in patients believed clinically or
pathologically to have ALSP.
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Table. Summary of Clinical, Radiologic, and Pathologic Findings
in ALSP Due to CSF1R andAARS2Mutations
Feature CSF1R AARS2
Mean age at
onset,
(range), y
45 (18-79) 29 (15-44)
Predominant
symptoms
Psychiatric changes,
cognitive decline,
parkinsonism, pyramidal
signs, ataxia, and seizures
Psychiatric changes, cognitive
decline, parkinsonism, pyramidal
signs, ataxia, and seizures;
ovarian failure is a distinguishing
feature in all women
Inheritance
pattern
Autosomal dominant but
may appear sporadic
Autosomal recessive but may
appear sporadic
Radiologic
appearance
Largely symmetric
confluent T2 hyperintense
and T1 hypointense
WM signal change:
frontoparietal, corpus
callosum, and pyramidal
tracts; punctate to
confluent areas of
restricted diffusion on
DWI; and periventricular
calcifications reported in
some patients
Largely symmetric confluent T2
hyperintense/T1 hypointense
WM signal change:
frontoparietal, corpus callosum,
and pyramidal tracts; punctate
to confluent areas of restricted
diffusion on DWI; periventricular
FLAIR suppression due to WM
rarefaction is a distinguishing
feature
CNS
pathologic
features
Axon and myelin loss;
frequent axonal spheroids
containing NF, p62, APP,
and β-amyloid; and
pigmented CD68-positive
microglia
Axon and myelin loss; frequent
axonal spheroids containing NF,
p62, APP, and β-amyloid;
pigmented CD68-positive
microglia
Muscle
pathologic
features
None reported to date Diffusely reduced cytochrome-c
oxidase staining is a
distinguishing feature
Abbreviations: AARS2, alanyl-transfer RNA synthetase 2; ALSP, adult-onset
leukoencephalopathy with axonal spheroids and pigmented glia; APP, amyloid
precursor protein; CNS, central nervous system; COX, cyclooxygenase;
CSF1R, colony-stimulating factor 1 receptor gene; DWI, diffusion-weighted
imaging; FLAIR, fluid-attenuated inversion recovery; NF, neurofilaments;
WM, white matter.
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